Considering that the ErbB2–nucleolin interaction enhances the oncogenic effects of ErbB220, and that inhibition of nucleolin with GroA appears to greatly affect cancer cells, we assumed that co-inhibition of both proteins may be beneficial in terms of cancer cell growth and tumorigenicity inhibition. The gene discussed is ERBB2; the disease is cancer.